Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.

Xiangyu ZhangLiang ZengYizhi LiQinqin XuHaiyan YangAnalyn LizasoXinru MaoRen'an JinYu ZengQinglin LiJianbo WangYang LiYong-Chang ZhangNong Yang

Published in: Cancer immunology, immunotherapy : CII (2021)

The combination of anlotinib and PD-1 inhibitor has promising efficacy and manageable toxicity as a second- or later-line treatment of relapsed NSCLC and possibly for relapsed SCLC.

Keyphrases

acute lymphoblastic leukemia
diffuse large b cell lymphoma
small cell lung cancer
multiple myeloma
hodgkin lymphoma
oxidative stress
combination therapy
smoking cessation
epidermal growth factor receptor